Mark E. Saad's most recent trade in Axsome Therapeutics Inc was a trade of 31,346 Common Stock done at an average price of $5.0 . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Saad E. Mark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.95 per share. | 31 Dec 2025 | 31,346 | 41,348 (0%) | 0% | 5.0 | 155,163 | Common Stock |
| Axsome Therapeutics Inc | E. Mark Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 31,346 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | E. Saad Mark | Director | Sale of securities on an exchange or to another person at price $ 165.18 per share. | 31 Dec 2025 | 31,346 | 10,002 (0%) | 0% | 165.2 | 5,177,732 | Common Stock |
| Axsome Therapeutics Inc | Saad E. Mark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.02 per share. | 31 Dec 2025 | 6,231 | 16,233 (0%) | 0% | 8.0 | 49,973 | Common Stock |
| Axsome Therapeutics Inc | E. Mark Saad | Director | Sale of securities on an exchange or to another person at price $ 165.18 per share. | 31 Dec 2025 | 6,231 | 10,002 (0%) | 0% | 165.2 | 1,029,237 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 6,231 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 9,127 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Sale of securities on an exchange or to another person at price $ 125.07 per share. | 05 Sep 2025 | 9,127 | 10,002 (0%) | 0% | 125.1 | 1,141,514 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.00 per share. | 05 Sep 2025 | 9,127 | 19,129 (0%) | 0% | 9 | 82,143 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 3,166 | 3,166 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,429 | 1,429 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,494 | 1,494 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 11,016 | 0 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 11 Sep 2024 | 11,016 | 21,018 (0%) | 0% | 3.7 | 40,429 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Sale of securities on an exchange or to another person at price $ 91.31 per share. | 11 Sep 2024 | 11,016 | 10,002 (0%) | 0% | 91.3 | 1,005,871 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 5,799 | 5,799 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | E. Mark Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 1,519 | 1,519 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 5,681 | 5,681 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 2,224 | 2,224 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 16,976 | 16,976 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 2,337 | 2,337 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.53 per share. | 17 Nov 2021 | 3,000 | 10,002 (0%) | 0% | 34.5 | 103,597 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.40 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.4 | 3,440 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.45 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.5 | 3,445 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Purchase of securities on an exchange or from another person at price $ 34.40 per share. | 17 Nov 2021 | 100 | 100 (0%) | 0% | 34.4 | 3,440 | Common Stock |
| Axsome Therapeutics Inc | Mark E. Saad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 7,325 | 7,325 | - | - | Stock Option (Right to Buy) |